Long-Term Retention, Efficacy, and Safety of Secukinumab in Moderate to Severe Plaque Psoriasis: Findings from a 5-Year SERENA Study - Report - MDSpire
Advertisement
Long-Term Retention, Efficacy, and Safety of Secukinumab in Moderate to Severe Plaque Psoriasis: Findings from a 5-Year SERENA Study
Clinical Report: Long-Term Retention, Efficacy, and Safety of Secukinumab
Overview
The SERENA study provides real-world evidence demonstrating that secukinumab maintains high treatment retention, sustained efficacy, and a consistent safety profile over a 5-year period in patients with moderate to severe plaque psoriasis. Significant improvements in skin clearance and quality of life were observed, underscoring the importance of early intervention.
Background
Plaque psoriasis is a chronic inflammatory condition that significantly impacts patients' quality of life and is associated with various comorbidities. Secukinumab, an IL-17A inhibitor, has shown promise in clinical trials, but long-term real-world data are essential to understand its durability and safety in routine practice. The SERENA study addresses this gap by evaluating secukinumab's long-term outcomes in a diverse patient population.
Data Highlights
No numerical data provided in the source material.
Key Findings
Secukinumab demonstrated high treatment retention rates over 5 years.
Patients experienced sustained improvements in skin clearance and quality of life.
The safety profile of secukinumab remained consistent throughout the study duration.
Early intervention with secukinumab is associated with better long-term outcomes.
The study included approximately 2700 patients across multiple European countries and Israel.
Clinical Implications
Secukinumab can be considered a valuable long-term treatment option for patients with moderate to severe plaque psoriasis, given its high retention rates and sustained effectiveness. Clinicians should consider early intervention with secukinumab to optimize patient outcomes and improve quality of life.
Conclusion
The SERENA study reinforces the role of secukinumab as an effective long-term treatment for plaque psoriasis, highlighting its benefits in real-world settings. Continued monitoring and evaluation of long-term safety and efficacy are essential for optimizing treatment strategies.
by Matthias Augustin, Paul-Gunther Sator, Ralph von Kiedrowski, Dimitris Rigopoulos, Marco Romanelli, Pierre-Dominique Ghislain, Tiago Torres, Dimitrios Ioannides, Cynthia Vizcaya, Andreas Clemens, Weibin Bao, Christelle C. Pieterse, Barbara Schulz, Piotr Jagiello, Curdin Conrad
